JPRN-jRCT2080222069已完成1 期
A Single-Dose and Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3002813 in Patients with Mild Cognitive Impairment due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 50age old 至 ot applicable（—）
- 性别
- All
入选标准
- •The study will enroll men or nonfertile women, at least 50 years of age with evidence of memory impairment on the Free and Cued Selective Reminding Test with Immediate Recall (FCSRT-IR), a Mini-Mental State Examination (MMSE) 16 to 30, no history of macrohemorrhage and no more than 4 microhemorrhages on magnetic imaging resonance (MRI), and a positive amyloid scan by florbetapir. Patients with contraindication for MRI, presence of >4 microhemorrhages on MRI, history or evidence on MRI of macrohemorrhage will be excluded.
排除标准
- 未提供
研究者
相似试验
招募中
1 期
Single-Dose and Multiple-Dose, Dose-Escalation Study with LY2599666 to Evaluate the Safety, Pharmacokinetics, and Tolerability in Healthy Subjects and Patients with Mild Cognitive Impairment Due to Alzheimer's Disease and Mild to Moderate Alzheimer's DiseaseHealthy/Mild Cognitive Impairment due to Alzheimer's Disease/Mild-to-moderate Alzheimer's DiseaseJPRN-jRCT2080223114Eli Lilly Japan K.K.
已完成
1 期
Single Ascending Dose and Multiple Ascending Dose Phase I study of PXS-4728A Administered Orally in Healthy Adult Males.Chronic Obstructive Pulmonary DiseaseRespiratory - Chronic obstructive pulmonary diseaseRespiratory - Other respiratory disorders / diseasesCystic FibrosisACTRN12614001326684Pharmaxis Ltd.72
进行中（未招募）
1 期
A study in healthy volunteers to look at the safety and tolerability of the test medicine VS-041 and how it is taken up by the body when given as single and multiple dosesHeart failure with preserved ejection fraction (HFpEF)Circulatory SystemISRCTN15814719Vasa Therapeutics Sp. z o. o.72
已完成
1 期
A study of the safety and pharmacokinetics and pharmacodynamics of the LOXL2 inhibitor PXS-5338K in healthy male subjects given single and repeated doses.ACTRN12617001444370Pharmaxis Ltd72
已完成
1 期
First-in-Human Study of RLYB116 in Healthy Participantscomplement mediated diseasesBlood - Haematological diseasesInflammatory and Immune System - Autoimmune diseasesACTRN12621001571864IPC Research, LLC89